tobira stock price
Why We Are Buying Tobira Therapeutics After A 'Failed' Phase 2 NASH Trial? We are reiterating a Buy rating on the common stock of Tobira Therapeutics with an updated price target (intrinsic value) of $34.88 using sum-of-the parts, enterprise DCF method. Tobira Therapeutics (NASDAQ: TBRA) announced the one-year results of a Phase 2 (CENTAUR) clinical trial in patients with non-alcoholic steato-hepatitis (NASH) on July 25.